BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17476915)

  • 1. [Final reply on the introduction of apolipoprotein determination in Jonkoping: need of ethical platform in the county council].
    Järhult B; Lindahl SO; Lindström K
    Lakartidningen; 2007 Mar 28-Apr 3; 104(13):1065. PubMed ID: 17476915
    [No Abstract]   [Full Text] [Related]  

  • 2. [The apoB/apoA-I ratio is better myocardial infarction marker than lipids].
    Walldius G; Angelin B; Eriksson M
    Lakartidningen; 2006 Mar 8-14; 103(10):751-2. PubMed ID: 16610201
    [No Abstract]   [Full Text] [Related]  

  • 3. [Plasma levels of apolipoproteins A-I, B and H in men after myocardial infarct].
    Choluj B; Votruba T; Sedlák F; Klestincová J; Matyska L
    Cas Lek Cesk; 1984 Nov; 123(47):1433-6. PubMed ID: 6439411
    [No Abstract]   [Full Text] [Related]  

  • 4. [Determination of apolipoproteins: An important tool for prevention and treatment of cardiovascular diseases].
    Wiklund O
    Lakartidningen; 2007 May 14-29; 104(20-21):1623-4. PubMed ID: 17564272
    [No Abstract]   [Full Text] [Related]  

  • 5. The relation of apolipoproteins A-I and B in children to myocardial infarction in parents.
    van Stiphout WA; Hofman A
    N Engl J Med; 1987 Feb; 316(9):548-9. PubMed ID: 3100955
    [No Abstract]   [Full Text] [Related]  

  • 6. Apolipoproteins A-I and B-markers in coronary risk evaluation.
    Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
    Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy.
    Walldius G; Jungner I
    Eur Heart J; 2005 Feb; 26(3):210-2. PubMed ID: 15618031
    [No Abstract]   [Full Text] [Related]  

  • 8. [A simple procedure for the simultaneous determination of apolipoproteins AI and B using rocket immunoelectrophoresis].
    Oswald B; Winkler L; Schlag B; Dargel R
    Z Med Lab Diagn; 1984; 25(8):411-6. PubMed ID: 6441367
    [No Abstract]   [Full Text] [Related]  

  • 9. Variation in plasma apolipoprotein A-1 and B concentrations following myocardial infarction.
    Shephard MD; Hester J; Walmsley RN; White GH
    Ann Clin Biochem; 1990 Jan; 27 ( Pt 1)():9-14. PubMed ID: 2106823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Should apolipoproteins be the first choice in routine health care?].
    Järhult B; Lindström K
    Lakartidningen; 2007 Oct 17-23; 104(42):3124. PubMed ID: 17985715
    [No Abstract]   [Full Text] [Related]  

  • 11. RIECA: an innovative immuno enzymatic competition assay for apolipoproteins AI and B determination.
    Galliani S; Tosi C; Guintini I; Mariani C; de Lalla C; Da Ros B; Rossi P; Baralle FE; Sidoli A
    Ann Biol Clin (Paris); 1990; 48(6):398-402. PubMed ID: 2121074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I've heard that a measurement called apo B may be better a predicting heart attacks than LDL cholesterol levels. Should I be tested for apo B?
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):8. PubMed ID: 15602781
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction.
    Gaeta G; Cuomo S; Capozzi G; Foglia MC; Barra S; Madrid A; Stornaiuolo V; Trevisan M
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):492-6. PubMed ID: 17962002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum.
    Riepponen P; Marniemi J; Rautaoja T
    Scand J Clin Lab Invest; 1987 Nov; 47(7):739-44. PubMed ID: 3685874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Blood levels of apolipoproteins A-I and B in individual types of hyperlipoproteinemias].
    Choluj B; Votruba T; Klestincová J; Matyska L
    Vnitr Lek; 1985 Jun; 31(6):530-3. PubMed ID: 3929467
    [No Abstract]   [Full Text] [Related]  

  • 16. Apolipoprotein B/A1 and risk of cardiovascular disease.
    Lind L
    Lancet; 2008 Jul; 372(9634):185-6. PubMed ID: 18640440
    [No Abstract]   [Full Text] [Related]  

  • 17. Apolipoproteins: promising biomarkers for cardiovascular risk prediction.
    Romero-Corral A; Somers VK; Lopez-Jimenez F
    J Intern Med; 2008 Jul; 264(1):1-3. PubMed ID: 18554334
    [No Abstract]   [Full Text] [Related]  

  • 18. Standardization of apolipoprotein measurements.
    Cooper GR; Smith SJ; Henderson LO; Hannon WH
    Prog Clin Biol Res; 1988; 255():155-74. PubMed ID: 3124130
    [No Abstract]   [Full Text] [Related]  

  • 19. [Total variation of LDL-cholesterol and apolipoprotein B/ Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks].
    Coşkun A
    Anadolu Kardiyol Derg; 2007 Sep; 7(3):331-2; author reply 332. PubMed ID: 17785232
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study.
    Pitsavos C; Panagiotakos DB; Skoumas J; Papadimitriou L; Stefanadis C
    Angiology; 2008; 59(3):335-41. PubMed ID: 18388068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.